Which has stronger earnings & valuation, DFTX or ANRO?

Alto Neuroscience is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A

Is DFTX or ANRO more profitable?

Alto Neuroscience's return on equity of -46.46% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% Alto Neuroscience N/A -46.46% -39.09%

Which has higher valuation and earnings, MANE or ANRO?

Veradermics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A -$70M -$1.90 N/A Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A

Is MANE or ANRO more profitable?

Veradermics' return on equity of 0.00% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Alto Neuroscience N/A -46.46% -39.09%

Alto Neuroscience (ANRO) Competitors

$30.30 -0.68 (-2.19%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$30.82 +0.52 (+1.73%)

As of 09/18/2026 07:30 PM Eastern

Compare

ANRO vs. AMRX, DFTX, MANE, INDV, and TARS

Should you buy Alto Neuroscience stock or one of its competitors? Alto Neuroscience's main competitors and comparable companies include Amneal Pharmaceuticals (AMRX), Definium Therapeutics (DFTX), Veradermics (MANE), Indivior (INDV), and Tarsus Pharmaceuticals (TARS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Alto Neuroscience compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Amneal Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Amneal Pharmaceuticals currently has a consensus price target of $20.14, indicating a potential upside of 7.66%. Alto Neuroscience has a consensus price target of $37.25, indicating a potential upside of 22.94%. Given Alto Neuroscience's higher possible upside, analysts plainly believe Alto Neuroscience is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Alto Neuroscience's net margin of 0.00%. Alto Neuroscience's return on equity of -46.46% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Alto Neuroscience	N/A	-46.46%	-39.09%

In the previous week, Amneal Pharmaceuticals had 11 more articles in the media than Alto Neuroscience. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 0 mentions for Alto Neuroscience. Amneal Pharmaceuticals' average media sentiment score of 0.49 beat Alto Neuroscience's score of -0.13 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Amneal Pharmaceuticals	Neutral
Alto Neuroscience	Neutral

Amneal Pharmaceuticals has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.98	$72.06M	$0.49	38.18
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Summary

Amneal Pharmaceuticals beats Alto Neuroscience on 12 of the 14 factors compared between the two stocks.

How does Alto Neuroscience compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Definium Therapeutics presently has a consensus price target of $64.88, suggesting a potential upside of 67.16%. Alto Neuroscience has a consensus price target of $37.25, suggesting a potential upside of 22.94%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Definium Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Definium Therapeutics had 43 more articles in the media than Alto Neuroscience. MarketBeat recorded 43 mentions for Definium Therapeutics and 0 mentions for Alto Neuroscience. Definium Therapeutics' average media sentiment score of 0.34 beat Alto Neuroscience's score of -0.13 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Definium Therapeutics	Neutral
Alto Neuroscience	Neutral

Definium Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Alto Neuroscience is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Alto Neuroscience's return on equity of -46.46% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Alto Neuroscience	N/A	-46.46%	-39.09%

27.9% of Definium Therapeutics shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Definium Therapeutics beats Alto Neuroscience on 9 of the 14 factors compared between the two stocks.

How does Alto Neuroscience compare to Veradermics?

Veradermics (NYSE:MANE) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Veradermics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

In the previous week, Veradermics had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 1 mentions for Veradermics and 0 mentions for Alto Neuroscience. Veradermics' average media sentiment score of 0.00 beat Alto Neuroscience's score of -0.13 indicating that Veradermics is being referred to more favorably in the media.

Company	Overall Sentiment
Veradermics	Neutral
Alto Neuroscience	Neutral

Veradermics' return on equity of 0.00% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Alto Neuroscience	N/A	-46.46%	-39.09%

Veradermics presently has a consensus target price of $153.00, suggesting a potential upside of 42.77%. Alto Neuroscience has a consensus target price of $37.25, suggesting a potential upside of 22.94%. Given Veradermics' stronger consensus rating and higher probable upside, equities analysts clearly believe Veradermics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Veradermics beats Alto Neuroscience on 7 of the 10 factors compared between the two stocks.

How does Alto Neuroscience compare to Indivior?

Indivior (NASDAQ:INDV) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, Indivior had 4 more articles in the media than Alto Neuroscience. MarketBeat recorded 4 mentions for Indivior and 0 mentions for Alto Neuroscience. Indivior's average media sentiment score of 1.04 beat Alto Neuroscience's score of -0.13 indicating that Indivior is being referred to more favorably in the media.

Company	Overall Sentiment
Indivior	Positive
Alto Neuroscience	Neutral

Indivior presently has a consensus target price of $45.17, suggesting a potential upside of 29.49%. Alto Neuroscience has a consensus target price of $37.25, suggesting a potential upside of 22.94%. Given Indivior's stronger consensus rating and higher possible upside, equities research analysts plainly believe Indivior is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Indivior has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.32	$210M	$2.79	12.50
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Indivior has a net margin of 26.65% compared to Alto Neuroscience's net margin of 0.00%. Alto Neuroscience's return on equity of -46.46% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Alto Neuroscience	N/A	-46.46%	-39.09%

Indivior has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

60.3% of Indivior shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Indivior beats Alto Neuroscience on 11 of the 15 factors compared between the two stocks.

How does Alto Neuroscience compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Tarsus Pharmaceuticals currently has a consensus price target of $94.00, suggesting a potential upside of 20.37%. Alto Neuroscience has a consensus price target of $37.25, suggesting a potential upside of 22.94%. Given Alto Neuroscience's higher probable upside, analysts plainly believe Alto Neuroscience is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Tarsus Pharmaceuticals had 4 more articles in the media than Alto Neuroscience. MarketBeat recorded 4 mentions for Tarsus Pharmaceuticals and 0 mentions for Alto Neuroscience. Tarsus Pharmaceuticals' average media sentiment score of 0.92 beat Alto Neuroscience's score of -0.13 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Tarsus Pharmaceuticals	Positive
Alto Neuroscience	Neutral

Alto Neuroscience has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	7.59	-$66.42M	-$1.09	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Tarsus Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Alto Neuroscience has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Alto Neuroscience	N/A	-46.46%	-39.09%

Summary

Tarsus Pharmaceuticals beats Alto Neuroscience on 9 of the 16 factors compared between the two stocks.

Get Alto Neuroscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANRO vs. The Competition

Export

Metric	Alto Neuroscience	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.22B	$12.48B	$7.25B	$23.13B
Dividend Yield	N/A	2.63%	2.57%	3.59%
P/E Ratio	-12.52	792.21	273.81	28.19
Price / Sales	N/A	945.09	692.78	20.33
Price / Cash	N/A	88.44	77.42	34.53
Price / Book	6.22	10.49	10.45	4.67
Net Income	-$63.24M	$2.81B	$3.48B	$1.07B
7 Day Performance	-5.34%	2.80%	0.88%	-1.64%
1 Month Performance	-13.31%	2.46%	-1.59%	-4.25%
1 Year Performance	734.71%	3.93%	18.08%	8.32%

Alto Neuroscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANRO Alto Neuroscience	1.7682 of 5 stars	$30.30 -2.2%	$37.25 +22.9%	+640.8%	$1.22B	N/A	N/A	68	High Trading Volume
AMRX Amneal Pharmaceuticals	3.3802 of 5 stars	$17.05 -2.2%	$19.00 +11.4%	+90.7%	$5.44B	$3.12B	34.80	8,500	Trending News Analyst Forecast
DFTX Definium Therapeutics	3.067 of 5 stars	$38.23 +0.4%	$63.00 +64.8%	+309.4%	$5.14B	N/A	N/A	40	Analyst Forecast
MANE Veradermics	2.0252 of 5 stars	$103.98 +5.6%	$153.00 +47.1%	N/A	$4.34B	N/A	N/A	19	Positive News Analyst Forecast
INDV Indivior	4.0803 of 5 stars	$34.32 -1.8%	$45.17 +31.6%	+52.4%	$4.05B	$1.24B	12.30	1,051	News Coverage Positive News Dividend Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANRO) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alto Neuroscience (ANRO) Competitors

ANRO vs. AMRX, DFTX, MANE, INDV, and TARS

How does Alto Neuroscience compare to Amneal Pharmaceuticals?

Summary

How does Alto Neuroscience compare to Definium Therapeutics?

Summary

How does Alto Neuroscience compare to Veradermics?

Summary

How does Alto Neuroscience compare to Indivior?

Summary

How does Alto Neuroscience compare to Tarsus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alto Neuroscience (ANRO) Competitors

ANRO vs. AMRX, DFTX, MANE, INDV, and TARS

How does Alto Neuroscience compare to Amneal Pharmaceuticals?

Which has more risk and volatility, AMRX or ANRO?

Do analysts prefer AMRX or ANRO?

Do institutionals & insiders believe in AMRX or ANRO?

Is AMRX or ANRO more profitable?

Does the media prefer AMRX or ANRO?

Which has stronger valuation & earnings, AMRX or ANRO?

Summary

How does Alto Neuroscience compare to Definium Therapeutics?

Do analysts prefer DFTX or ANRO?

Does the media favor DFTX or ANRO?

Which has more volatility & risk, DFTX or ANRO?

Which has stronger earnings & valuation, DFTX or ANRO?

Is DFTX or ANRO more profitable?

Do insiders and institutionals have more ownership in DFTX or ANRO?

Summary

How does Alto Neuroscience compare to Veradermics?

Which has higher valuation and earnings, MANE or ANRO?

Does the media favor MANE or ANRO?

Is MANE or ANRO more profitable?

Do analysts prefer MANE or ANRO?

Summary

How does Alto Neuroscience compare to Indivior?

Does the media favor INDV or ANRO?

Do analysts rate INDV or ANRO?

Which has preferable valuation and earnings, INDV or ANRO?

Is INDV or ANRO more profitable?

Which has more risk and volatility, INDV or ANRO?

Do insiders & institutionals believe in INDV or ANRO?

Summary

How does Alto Neuroscience compare to Tarsus Pharmaceuticals?

Do analysts recommend TARS or ANRO?

Do insiders and institutionals believe in TARS or ANRO?

Does the media refer more to TARS or ANRO?

Which has stronger earnings & valuation, TARS or ANRO?

Which has more risk & volatility, TARS or ANRO?

Is TARS or ANRO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools